A second update on mapping the human genetic architecture of COVID-19
Masahiro Kanai, Shea J. Andrews, Mattia Cordioli, Christine Stevens, Benjamin M. Neale, Mark J. Daly, Andrea Ganna, Gita A. Pathak, Akiko Iwasaki, Juha Karjalainen, Juha Mehtonen, Matti Pirinen, Karolina Chwiałkowska, Amy Trankiem, Mary K. Balaconis, Kumar Veerapen, Brooke N. Wolford, Hajar Fauzan Ahmad, Kathrin Aprile von Hohenstaufen Puoti, Cindy G. Boer, Palwendé Romuald Boua, Guillaume Butler‐Laporte, Carmen L. Cadilla, Francesca Colombo, Venceslas Douillard, Nicole Dueker, Atanu Kumar Dutta, Yasser M. El‐Sherbiny, Madonna M. Eltoukhy, Sahar Esmaeeli, Annika Faucon, Marie-Julie Favé, Israel Fernández Cadenas, Margherita Francescatto, Laurent C. Francioli, Lude Franke, Macarena Fuentes‐Guajardo, Rocío Gallego Durán, David Gómez-Cabrero, Emi N. Harry, Philip R. Jansen, József Szentpéteri, Elżbieta Kaja, Chloe Kirk, Athanasios Kousathanas, José Eduardo Krieger, Sanjay Patel, Audrey Lemaçon, Sophie Limou, Píetro Lió, Eirini Marouli, M. Marttila, Carolina Medina‐Gómez, Yael Michaeli, Isabelle Migeotte, Soumyajit Mondal, Andrés Moreno‐Estrada, Leire Moya, Tomoko Nakanishi, Jamal Nasir, Dorote Pasko, Nathaniel M. Pearson, Alexandre C. Pereira, James R. Priest, Vid Prijatelj, Ivana Nedeljković, Alexander Teumer, Réka Várnai, Manuel Romero‐Gómez, Christina Roos, Jeffrey Rosenfeld, Ruolin Li, Eva C. Schulte, Claudia Schurmann, Bahareh Sedaghati-khayat, Doaa Shaheen, Ilangumaran Shivanathan, Csilla Sipeky, Zhou Sirui, Pasquale Striano, Yosuke Tanigawa, Alicia Utrilla Remesal, Nirmal Vadgama, Costanza L. Vallerga, Sander W. van der Laan, Ricardo A. Verdugo, Qingbo S. Wang, Wei Zhou, Ummu Afeera Zainulabid, Ruth N. Zárate, Adam Auton, Janie F. Shelton, Anjali J. Shastri, Catherine H. Weldon, Teresa Filshtein-Sonmez, Daniella Coker, Antony SymonsNature2023 · DOI · OpenAlex
Abstract: Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.
Introduction
The extreme variability in human response to SARS-CoV-2—ranging from asymptomatic infection to critical respiratory failure—remains a central challenge in the global health response. While clinical risk factors like age and comorbidities are significant, they do not fully account for this clinical spectrum. The COVID-19 Host Genetics Initiative (HGI) "Release 7" meta-analysis identifies host genetics as a critical determinant, mapping 51 genetic loci associated with COVID-19 outcomes. This research moves beyond simple identification of risk spots to delineate the specific biological pathways governing viral entry, mucosal defense, and immune response.
Methods and Global Data Representation
The study represents a massive international collaboration, performing a meta-analysis across 82 studies from 35 countries. The primary dataset encompasses 219,692 cases and over 3 million controls. Researchers utilized a two-class Bayesian model to categorize genetic variants by their influence on either susceptibility (the likelihood of infection) or severity (the likelihood of critical illness).
Global distribution of studies and genetic ancestry composition in the COVID-19 HGI Release 7.
As shown in Figure 1, the initiative made a concerted effort to include diverse populations, incorporating 36 studies with non-European ancestries. However, data remains predominantly skewed toward European populations (EUR), highlighting a persistent challenge in global genomic research.
Three Tiers of Biological Defense
The 51 identified loci converge on three distinct biological systems that form the human defense against COVID-19:
Viral Entry Mechanisms: Genes such as ACE2 and TMPRSS2 are central to the virus's ability to enter human cells. A specific intronic variant in TMPRSS2 (rs9305744) was found to be significantly protective against critical illness (OR = 0.92), confirming the protease as a high-priority therapeutic target.
Airway Mucus Barrier: Several mucin genes (MUC1, MUC4, MUC5B, MUC16) were identified. These genes encode the structural components of airway mucus, acting as the primary physical barrier. Interestingly, these variants mostly influence susceptibility—the initial "wall" the virus encounters.
Type I Interferon Response: Genes involved in the interferon pathway (e.g., JAK1, IFNA10) are strongly linked to disease severity. If this early-warning immune system is genetically compromised, the virus can replicate unchecked, leading to severe clinical outcomes.
Key Results and Pleiotropic Relationships
The study confirms that susceptibility and severity are genetically distinct; 36 loci were linked to severity, while only 9 were linked to susceptibility. Mendelian Randomization (MR) confirmed that smoking is causally associated with increased COVID-19 risk, while better kidney function is protective.
Additionally, Phenome-wide association studies (PheWAS) revealed a "lung function paradox." Some variants that increase COVID-19 risk are associated with better baseline lung function in non-COVID contexts, suggesting complex evolutionary trade-offs. SNP-based heritability for the analyzed phenotypes was estimated between 1.2% and 8.2%.
Limitations and Future Directions
A significant limitation is that most data were collected before widespread vaccination; the genetic variants influencing outcomes may shift as population immunity evolves. Furthermore, the ancestry bias toward European populations necessitates continued efforts to include diverse global cohorts. Future work will focus on fine-mapping these loci to specific cell types in the lung and immune system to translate these genetic signals into targeted drug discovery.
Summary updated
Abstract
Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.
BibTeX
@inproceedings{kanai2023second,
author = {Masahiro Kanai and Shea J. Andrews and Mattia Cordioli and Christine Stevens and Benjamin M. Neale and Mark J. Daly and Andrea Ganna and Gita A. Pathak and Akiko Iwasaki and Juha Karjalainen and Juha Mehtonen and Matti Pirinen and Karolina Chwiałkowska and Amy Trankiem and Mary K. Balaconis and Kumar Veerapen and Brooke N. Wolford and Hajar Fauzan Ahmad and Shea J. Andrews and Kathrin Aprile von Hohenstaufen Puoti and Cindy G. Boer and Palwendé Romuald Boua and Guillaume Butler‐Laporte and Carmen L. Cadilla and Karolina Chwiałkowska and Francesca Colombo and Venceslas Douillard and Nicole Dueker and Atanu Kumar Dutta and Yasser M. El‐Sherbiny and Madonna M. Eltoukhy and Sahar Esmaeeli and Annika Faucon and Marie-Julie Favé and Israel Fernández Cadenas and Margherita Francescatto and Laurent C. Francioli and Lude Franke and Macarena Fuentes‐Guajardo and Rocío Gallego Durán and David Gómez-Cabrero and Emi N. Harry and Philip R. Jansen and József Szentpéteri and Elżbieta Kaja and Masahiro Kanai and Chloe Kirk and Athanasios Kousathanas and José Eduardo Krieger and Sanjay Patel and Audrey Lemaçon and Sophie Limou and Píetro Lió and Eirini Marouli and M. Marttila and Carolina Medina‐Gómez and Yael Michaeli and Isabelle Migeotte and Soumyajit Mondal and Andrés Moreno‐Estrada and Leire Moya and Tomoko Nakanishi and Jamal Nasir and Dorote Pasko and Nathaniel M. Pearson and Alexandre C. Pereira and James R. Priest and Vid Prijatelj and Ivana Nedeljković and Alexander Teumer and Réka Várnai and Manuel Romero‐Gómez and Christina Roos and Jeffrey Rosenfeld and Ruolin Li and Eva C. Schulte and Claudia Schurmann and Bahareh Sedaghati-khayat and Doaa Shaheen and Ilangumaran Shivanathan and Csilla Sipeky and Zhou Sirui and Pasquale Striano and Yosuke Tanigawa and Alicia Utrilla Remesal and Nirmal Vadgama and Costanza L. Vallerga and Sander W. van der Laan and Ricardo A. Verdugo and Qingbo S. Wang and Wei Zhou and Ummu Afeera Zainulabid and Ruth N. Zárate and Adam Auton and Janie F. Shelton and Anjali J. Shastri and Catherine H. Weldon and Teresa Filshtein-Sonmez and Daniella Coker and Antony Symons},
title = {{A second update on mapping the human genetic architecture of COVID-19}},
booktitle = {Nature},
year = {2023},
doi = {10.1038/s41586-023-06355-3},
}